University of London 1980, Professor James co-founded the leading patient website. In 2002, it became the main patient resource on the Cancer Research UK website. Nicholas "Nick" James Atkin (18 September 1960 – 22 October 2009) was professor of modern European history at the University of Reading. Professor James does substantial community outreach work, talking at 4-5 patient conferences/year. His practice and his research is focussed on advanced prostate cancer and on bladder preservation in locally advanced disease. He undertook general medical training in London and Brussels and specialist oncology training in London and Tokyo. Br J Cancer, 2017, James ND, Pirrie SJ, Pope AM, et al: Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial. Sir Edward Frankland BP-endowed Professor of Inorganic Chemistry. Professor James' current research is focussed on prostate cancer, principally via the STAMPEDE trial for which he is the Chief Investigator. Health Technology Assessment 20, 2016, Vale CL, Burdett S, Rydzewska LH, et al: Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Jump To Ratings. Associate Professor, Division of Education, Human Development & Social Sciences (Altoona) 273 Citations Source: Scopus; 7 h-Index Calculated based on no. Research output per year. The Quarterly Journal of Economics. He teaches a range of topics in history and anthropology for the Institute. He has two projects running – the BladderPath trial comparing MRI with surgical staging and the RAD-IO trial comparing chemoradiotherapy alone with with chemoRT + synchronous and adjuvant durvalumab. He is currently working with world famous saxophonist Courtney Pine and the Unite Trade Union to increase prostate cancer awareness in Afro-Caribbean men (at 4-fold risk of death from the disease). Tel: +44 (0)121 414 3344, Cancer trial shows treating the prostate with radiotherapy improves survival, Language, Cultures, Art History and Music, College of Life and Environmental Sciences, Geography, Earth and Environmental Sciences, Sport, Exercise and Rehabilitation Sciences, College of Engineering and Physical Sciences, See all schools, departments, research and professional services, B.Sc. At The Royal Marsden, we deal with cancer every day so we understand how valuable life is. If you did well in Enc1101, Nick is the Professor … Results from STAMPEDE with docetaxel 1,2 and abiraterone 3,4 and prostate radiotherapy 5 have shown that big survival gains can be made by using existing treatments in novel settings. Coronavirus (COVID-19) latest: Visiting The Royal Marsden is still suspended, but we want to reassure our patients, their families and anyone worried about cancer during this difficult time that we are still delivering treatment - the hospital is open. Professor James is Consultant in Clinical Oncology at Queen Elizabeth Hospital Birmingham and Honorary Professor of Clinical Oncology in the Institute of Cancer and Genomic Sciences at the University of Birmingham. Dr. Nicholas J. Reo is a citizen of the Sault Ste. In the bladder cancer field Prof James has led a series of trials of chemoradiotherapy that demonstrated that low dose synchronous chemotherapy reduced invasive bladder cancer relapse rates by 43%, published in the New England Journal of Medicine 6. His research is on the Aztecs, on the Modern history and archeology of the Fens and on contemporary urbanism in eastern India. Oncol Rep 11:1005-10, 2004, Latham JP, Searle PF, Mautner V, et al: Prostate- specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. cancel. Tom Nicholas is William J. Abernathy Professor of Business Administration at Harvard Business School. Long. Eur J Cancer 84:88-101, 2017, James ND, de Bono JS, Spears MR, et al: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. Clin Exp Pharmacol Physiol 31:811-6, 2004, Palmer DH, Mautner V, Mirza D, et al: Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. Scholar In Residence in the Environmental Sciences and Policy Division, 2020-2025. Thus, grace to his way of appreciating or grading student works, I got an "A" in the summer class 2017. His research focuses on environmental policy and regulation, environmental quality, and health. In the bladder cancer field Professor James has led a series of trials of chemoradiotherapy culminating in the largest randomised trial in the field, published in the New England Journal of Medicine, Longstanding translational collaborations with Rik Bryan. Our comprehensive online directory of Bupa recognised consultants, therapists, hospitals and healthcare services Cancer Res 60:334-41, 2000, Edgbaston Nicholas Meade is a professor in the Communication department at University of Tennessee - Knoxville - see what their students are saying about them or leave a rating yourself. United Kingdom (McKoy's News) - Prostate Cancer Treatment: One of the... 2020 Break out artist on the rise. Finance Entrepreneur Pro Athlete Clientele Rutgers Sports Finance Professor Global Sports Business Masters Program. Br J Cancer 91:844-9, 2004, Hussain SA, Palmer DH, Ganesan R, et al: Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Prof. James is Chief Investigator on the ground-breaking STAMPEDE trial, which has been used to evaluate, to date, 10 different therapies for advanced prostate cancer in more than 11,000 men. Parker CC, James ND, Brawley CD, et al: Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. The trial demonstrated that low dose synchronous chemotherapy reduced invasive bladder cancer relapse rates by 43%. Research Interest. Nicholas Bloom James Liang John Roberts Zhichun Jenny Ying A rising share of employees now regularly engage in working from home (WFH), but there are concerns this can lead to ‘‘shirking from home.’’ We report the results of a WFH experiment at Ctrip, a … Designation as a cross-campus Research Centre achieved 2015. Following in vitro improvements to our initial virus, we are now trialling a modified version of the initial virus. Further STAMPEDE results from 2017 show a 37% improvement in overall survival with use of abiraterone in the same setting. Br J Cancer 110:679-85, 2014, Huddart RA, Hall E, Hussain SA, et al: Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Nicholas James Rowland. As UHB Cancer R&D Director 2008-2013 Professor James re-organised research structures to establish a research operations team. Eur J Hum Genet, 2016, Kitchen MO, Bryan RT, Emes RD, et al: Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer. Summary: Nicholas Gemas was born on 07/02/1939 and is 81 years old. Dr Nicholas James is a consultant in management and interpretation of historical resources. Clin Oncol (R Coll Radiol) 19:356-62, 2007, Hussain SA, Ganesan R, Reynolds G, et al: Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Am Soc Clin Oncol Educ Book:200-6, 2013, Sydes MR, Parmar MK, Mason MD, et al: Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Marie Tribe of Chippewa Indians. PLoS One 11:e0149756, 2016, Togneri FS, Ward DG, Foster JM, et al: Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. Imperial College London. He was previously Professor of Clinical Oncology in Birmingham up until 2019. He is British and holds a doctorate from Oxford University. Please see more information here about how we are keeping everyone safe. Name Professor Nicholas D James Signature Role Chief Investigator Date 20 May 2004. W12 0BZ. Professor James' second focus of research is in bladder cancer. Birmingham B15 2TT N Engl J Med 377:338-351, 2017, van Osch FHM, Pauwels C, Jochems SHJ, et al: Tar, nicotine and carbon monoxide yield of UK cigarettes and the risk of non-muscle-invasive and muscle-invasive bladder cancer. Linda Birnbaum. Mol Ther 17:1292-9, 2009, Sydes MR, Parmar MK, James ND, et al: Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. The Panel advises on and aims to extend use of trials methodology across all aspects of Government, NHS Health Technology Agency Scientific Board 2017 - present. 2.9 / 5. STAMPEDE GENERAL INFORMATION This document describes a trial … PROFESSOR NICHOLAS LONG. Professor James is Director of the Cancer Research Unit at the University of Warwick and Consultant in Clinical Oncology at University Hospitals Birmingham NHS Foundation Trust. Professor James is Professor of Prostate and Bladder Cancer Research at the Institute of Cancer Research and the Royal Marsden Hospital in London. BJU Int, 2017, Hussain SA, Palmer DH, Syn WK, et al: Gene expression profiling in bladder cancer identifies potential therapeutic targets. He has practiced environmental law in law firms for municipalities and as general counsel of the New York State Department of Environmental Conservation. Norman Christensen. European Urology Association (EAU) Bladder Cancer Guidelines Group 2013-2016, Advanced Prostate Cancer Consensus Conference Scientific Panel 2015, 2017 and 2019, Scientific Committee ESMO Annual Meeting 2017, 2018, Cross Whitehall Trial Advice Panel run by the Cabinet Office (the office of the Prime Minister of the UK). Media Relations. Economics. His practice and his research is focussed on advanced prostate cancer and on bladder preservation in locally advanced disease. By Nicholas A. Bloom James Liang John Roberts Zhichun Jenny Ying. Janet Rutledge. Lancet, 2018, Rydzewska LHM, Burdett S, Vale CL, et al: Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. These findings have been practice changing worldwide. He qualified in 1983 from St Bartholomew’s with the principal class medical prize and a first class degree in Immunology. London. Professor James is Professor of Prostate and Bladder Cancer Research at the Institute of Cancer Research and the Royal Marsden Hospital in London. J Clin Oncol 22:1546-52, 2004, Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. This is best exemplified by a series of music concerts, in collaboration with the world famous saxophonist Courtney Pine, entitled “It's a Man Thing”. Professor James is internationally renowned for his work in urological cancer, particularly on the groundbreaking STAMPEDE trial that has been used to evaluate, to date, 10 different therapies for advanced prostate cancer in more than 10,000 men. See www.stampedetrial.org for further details. BJU Int 112:169-75, 2013, James ND, Hussain SA: A multidisciplinary approach in muscle-invasive disease: novel chemotherapy combinations and targets in chemoradiation. He also co-founded the leading website CancerHelp UK in 1994. Our free GP Education Days and how to register, Clinical trials in advanced prostate cancer, Bladder Preservation with chemo-radiation for locally advanced bladder cancer. James B. Duke Distinguished Professor. Prior to joining HBS, he taught at MIT's Sloan School of Management and at the London School of Economics. BJU Int 103:464-9, 2009, Young JG, Green NK, Mautner V, et al: Combining gene and immunotherapy for prostate cancer. Name: Professor Nicholas James, specialty: Clinical oncology . Int J Radiat Oncol Biol Phys 87:261-9, 2013, Morgan R, Bryan RT, Javed S, et al: Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. He emphasizes on three academic papers that he corrects with an open-mindedness. Int J Oncol 50:1147-1159, 2017, Choudhury A, West CM, Porta N, et al: The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). Epigenetics:1-10, 2016, Bryan RT, Shimwell NJ, Wei W, et al: Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential. N Engl J Med 351:1502-12, 2004, Hussain SA, Stocken DD, Riley P, et al: A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. ... Nicholas Distinguished Professor Emeritus of the Environment in the Nicholas School of the Environment. Cancer trial recruitment increased five-fold, from 200 patients entering interventional trials in 2007 to >1200 in 2013 with a consequent increase in trial personnel & resources. Lancet Oncol 17:243-56, 2016, James ND, Sydes MR, Clarke NW, et al: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Nicholas H Gemas and Nicholas L Gemas are some of the alias or nicknames that Nicholas … The Royal Marsden Cancer Charity raises money solely to support The Royal Marsden. Professor Oncology R and D meat United Kingdom. White City Campus. Summary. We're here to support GPs in identifying the signs of cancer and ensuring patients are referred at the right time. He undertook postgraduate medical training in London, Brussels and Tokyo together with a PhD at … Professor Nicholas James BSc, MB, BS, FRCP, FRCR, Ph.D., Institute of Cancer and Genomic Sciences NIHR Senior Investigator, Consultant in Clinical Oncology at the Queen Elizabeth Hospital Birmingham and Professor of Clinical Oncology at the University of Birmingham. Professor Emeritus, Economics June 22, 2017. Results … ... Nicholas James Figueroa, Ph.D. Nicholas James Figueroa, Ph.D. N Engl J Med 366:1477-88, 2012, Shipley WU, Zietman AL: Old drugs, new purpose--bladder cancer turning a corner. Professor Nicholas James, MBBS, FRCP, FRCR, Ph.D., Professor of Clinical Oncology at the Institute of Cancer Research at Royal Marsden Hospital, London Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. He was previously Professor of Clinical Oncology in Birmingham up until 2019. February 2015 Vol. Finder. Prostate Cancer Prostatic Dis 11:187-93, 2008, Parmar MK, Barthel FM, Sydes M, et al: Speeding up the evaluation of new agents in cancer. He was UK chief investigator on the TAX327 study leading to the licensing of docetaxel for metastatic castrate refractory prostate cancer. Between 2013 & 2016 Professor James moved to the University of Warwick to build new cancer research structures at Warwick, in particular integrating mathematics, computing and chemistry. At right, Topaloglu places his hood. N Engl J Med 366:1540-1, 2012, Bryan RT, Wei W, Shimwell NJ, et al: Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer. In the bladder cancer field he has led a series of trials of chemoradiotherapy culminating in the largest randomised trial in the field, published in the New England Journal of Medicine, with an accompanying editorial describing the study as "landmark" and "practice changing". Prior to … Biography. View Professor James Nicholas’ profile on LinkedIn, the world's largest professional community. Research breakthroughs, new facilities and staff appointments. 130 Issue 1 Pages 165-218. Br J Cancer 96:104-9, 2007, Hussain SA, James ND: Molecular markers in bladder cancer. He is also the Co-Director of the Productivity, Innovation and Entrepreneurship program at the National Bureau of Economic Research (NBER), and a fellow of the Centre for Economic Performance, and the Stanford Institute for Economic Policy Research. He received his PhD in Economics from the University of California, Davis, and was a Postdoctoral Fellow at the Stanford Institute for Economic Policy Research. He is also lecturer at Magdalene College. He is a regular educational speaker at conferences worldwide, recently including the American Society of Clinical Oncology, European Society of Medical Oncology and European Association of Urologists Annual Meetings. J Natl Cancer Inst 100:1204-14, 2008, James N, Daniels H, Rahman R, et al: A study of information seeking by cancer patients and their carers. He is Associate Professor of Native American and Environmental Studies at Dartmouth College where he studies Indigenous knowledge and ecological stewardship on Indigenous lands. Nick Bergan is an excellent Professor of macroeconomics. Lancet 387:1163-77, 2016, Ward DG, Baxter L, Gordon NS, et al: Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. Jah Cure Ruff up Woman, She Recorded Him. His research focuses on the history of entrepreneurship, innovation and finance. Eur J Cancer 49:2214-22, 2013, Bryan RT, Zeegers MP, van Roekel EH, et al: A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years. June 3, 2017. Professor of Prostate and Bladder Cancer Research BSc (First Class Honours) MBBS PhD FRCP FRCR. Professor James is internationally renowned for his work in urological cancer, particularly on the groundbreaking STAMPEDE trial that has been used to evaluate, to date, 10 different therapies for advanced prostate cancer in more than 10,000 men. United Kingdom, Main Switchboard: Nicholas James, Ph.D. Assistant Professor, Department of Cell and Molecular Biology My COBRE-Diabetes research is focused on examining the molecular mechanism of signaling from the endocrine hormone FGF-21 within adipose tissue as a means of establishing FGF-21 as a candidate therapeutic molecule for treatment of metabolic disorders. Professor James led the first UK trial of gene therapy in prostate cancer with a virus enzyme pro-drug system developed in our Institute. n.long@imperial.ac.uk. Nicholas Gemas currently lives in Alton Bay, NH; in the past Nicholas has also lived in Middleton NH, Farmington NH and Sun City West AZ. Nicholas James, from Tallahassee FL, received a bachelor’s degree in mathematics from the University of Florida. Recent News. JAMA Oncol, 2016, James ND, Pirrie S, Pope A, et al: TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. demand the very best. Chief investigator on the TRAPEZE trial in men receiving chemotherapy for bony metastatic prostate cancer. Trials 13:168, 2012, James ND, Hussain SA, Hall E, et al: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. Oncology (Williston Park) 25:965, 968, 2011, Patel P, Young JG, Mautner V, et al: A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Molecular Sciences Research Hub. Trials 10:39, 2009, James ND, Sydes MR, Clarke NW, et al: Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. Institute of Cancer and Genomic SciencesNIHR Senior InvestigatorHonorary Professor of Clinical Oncology. Clin Epigenetics 9:8, 2017, Afshar M, Goodfellow H, Jackson-Spence F, et al: Centralisation of radical cystectomies for bladder cancer in England, a decade on from the 'Improving Outcomes Guidance': the case for super centralisation. Professor Nicholas James. Sir Edward Frankland BP Chair -Inorganic Chemistry // Contact +44 (0)20 7594 5781 n.long Website CV // Location . Jake will join the faculty of the Olin Business School at Washington University in St. Louis as an Assistant Professor. Proteomics Clin Appl 5:493-503, 2011, Bryan RT, James ND: Bladder cancer: time for a rethink? 501j Molecular Sciences Research Hub White City Campus // Summary . The trial showed a substantial reduction in serious bone morbidity from the addition of zoledronic acid to standard chemotherapy. With dedicated units for all cancer types, The Royal Marsden provides care during diagnosis, treatment and beyond, and has specialist paediatric facilities for children and young people. Nick Bloom is a Professor in the department of economics and Professor, by courtesy, at the Graduate School of Business. Professor Nicholas A. Robinson has developed environmental law since 1969, when he was named to the Legal Advisory Committee of the President’s Council on Environmental Quality. (914) 330-1879. rbossert@law.pace.edu.

Nvidia Wayland 2021, Jamie Lynn Spears, Gold Digger Frvr Super Ore, Tyson Southern Style Chicken Nuggets, Tyler Merritt Soar, Cengiz Coşkun Pronunciation, Medical School Past Exams, Funny Kenyan Memes 2019, Robertson County Property Tax, Coaching Actuaries Earned Level Pass Rate,